RxDoctor Payments Data

Anirban Ghosh, MD

Internal Medicine · Kearney, NENPI 1790063014

Payments from drug & device makers

$409in general payments, 2019–2025

Across 18 payments — averaging $22.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$143
  • AbbVie$108
  • Kerecis Limited$48
  • Novo Nordisk$31
  • Lilly USA, LLC$28
  • Sanofi$21
  • plus $30 from 2 others

What the payments were for

  • Food & beverage$409100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer3$143
AbbVie(2 entities)7$108
Kerecis Limited1$48
Novo Nordisk2$31
Lilly USA, LLC2$28
Sanofi1$21
Gilead1$15
Philips North America LLC1$15

How this compares

$409 in reported general payments places this provider in the 70th percentile of 570 internal medicine providers in Nebraska.

See all internal medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$132,897
Medicare patients
499
Services billed
1,599

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin225$162,133
OzempicSemaglutide105$117,640
XareltoRivaroxaban131$77,612
TrulicityDulaglutide52$56,984
EliquisApixaban90$47,219
MounjaroTirzepatide34$36,856
Tresiba Flextouch U-200Insulin Degludec28$28,068
Humulin R U-500Insulin Regular, Human12$18,632
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$16,717
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$15,436
Tresiba Flextouch U-100Insulin Degludec27$14,011
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/713$12,828
MyrbetriqMirabegron31$12,555
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$11,294
Budesonide25$10,551

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$31$117,640105 claims
Lilly USA, LLCTrulicity, Mounjaro$28$93,84086 claims
PfizerEliquis$143$47,21990 claims
AbbVieLinzess$108$6,38412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 570 internal medicine providers in Nebraska.

Other internal medicine in Kearney

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →